Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Alkaloids from In Vitro Cultured <i>Rhodophiala pratensis</i> Display Neuroprotective Effects in Murine Microglial Cell Models of Inflammation.

Plants (Basel, Switzerland)·2026
Same author

Timing of microglial ablation determines protection from tau-mediated neurodegeneration and cognitive decline.

Acta neuropathologica communications·2026
Same author

Potent Nrf2-Inducing C6-Isothiocyanate Glucose Derivatives with Dual Antioxidant and Antitumor Activity.

Antioxidants (Basel, Switzerland)·2026
Same author

Long-term NRF2-driven microglial repopulation mitigates microgliosis, neuronal loss and cognitive deficits in tauopathy.

Brain, behavior, and immunity·2026
Same author

[Nutritional support in cancer patients - Perceptions of healthcare professionals and patients].

Nutricion hospitalaria·2025
Same author

Repurposed Drugs to Enhance the Therapeutic Potential of Oligodendrocyte Precursor Cells Derived from Adult Rat Adipose Tissue.

Cells·2025

Related Experiment Video

Updated: Jun 27, 2025

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.8K

Innovative pathological network-based multitarget approaches for Alzheimer's disease treatment.

Paloma Mayo1,2,3, Jorge Pascual1,3, Enrique Crisman3

  • 1Departamento de desarrollo preclínico, Fundación Teófilo Hernando, Las Rozas, Madrid, Spain.

Medicinal Research Reviews
|April 28, 2024
PubMed
Summary

Alzheimer's disease (AD) is a growing global health threat. This review explores multitarget drug development strategies aimed at addressing the complex pathology of AD by targeting multiple pathways simultaneously.

Keywords:
Alzheimer's diseasedrug targets combinationsmultifactorial diseasemultitarget drugsmultitarget‐directed ligandspolypharmacology drug

More Related Videos

Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.3K

Related Experiment Videos

Last Updated: Jun 27, 2025

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-&#946; and Tau Neuropathology
10:02

Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology

Published on: May 28, 2017

26.8K
Author Spotlight: Advancing Alzheimer's Research &#8211; Exploring Early Detection and Multi-Omics Approaches
09:47

Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches

Published on: December 15, 2023

1.0K
Fabrication of Amyloid-&#946;-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease
06:52

Fabrication of Amyloid-β-Secreting Alginate Microbeads for Use in Modelling Alzheimer's Disease

Published on: July 6, 2019

9.3K

Area of Science:

  • Neuroscience
  • Medicinal Chemistry
  • Pharmacology

Background:

  • Alzheimer's disease (AD) is the most common neurodegenerative disorder, posing a significant global health challenge.
  • The prevalence of AD is expected to rise sharply in the coming decades due to an aging population.
  • Current AD treatments offer only symptomatic relief and do not halt disease progression.

Purpose of the Study:

  • To review the progress in multitarget drug development for Alzheimer's disease over the past decade.
  • To highlight the strategy of using multitarget-directed ligands to address the complex, multifactorial nature of AD.
  • To discuss how targeting multiple pathological nodes may offer a more effective therapeutic approach.

Main Methods:

  • Literature review of scientific publications and drug development pipelines.
  • Analysis of multitarget drug strategies and their underlying pharmacological principles.
  • Examination of the impact of novel pathological pathway discoveries on medicinal chemistry for AD.

Main Results:

  • The development of multitarget drugs has gained momentum in AD research.
  • These drugs are designed to interact with multiple targets within the complex AD pathological network.
  • The review focuses on advancements in medicinal chemistry and drug design over the last ten years.

Conclusions:

  • Multitarget drug development represents a promising strategy for combating Alzheimer's disease.
  • By engaging multiple pathological pathways, these agents aim to delay or halt disease progression.
  • Continued research into the complex interplay of AD pathologies is crucial for advancing therapeutic options.